HCW Biologics Inc., a U.S.-based clinical-stage biopharmaceutical company, has solidified a license agreement with WY Biotech Co., Ltd., a China-based company, for the development and commercialization of HCW11-006, a novel immunotherapy molecule. This agreement, now fully binding, follows the completion of due diligence by WY Biotech. HCW Biologics has earned a $7.0 million upfront license fee and will recognize this revenue in the second quarter of 2025. The company is also eligible for further development milestone payments and double-digit royalties on future sales. Under the agreement, WY Biotech will manage all costs related to the molecule's development, while HCW Biologics retains an option to recapture commercial rights in the Americas after a Phase 1 trial. Both companies will collaborate globally on clinical development and partnering efforts.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。